Literature DB >> 22052888

Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers.

Chia-Ming Chu1, Yun-Fan Liaw.   

Abstract

In 118 previous hepatitis B surface antigen (HBsAg) carriers, low-level hepatitis B (HBV) viremia persisted at a rate of 15%-20% for >10 years after HBsAg seroclearance. The frequency of HBV viremia was significantly (P = .002) lower in patients with anti-HBsAg seroconversion (6 of 69 [8.7%]) than in those without seroconversion (15 of 49 [30.6%]).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22052888     DOI： 10.1093/cid/cir755

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

2.  Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.

Authors:  Xiao Lin; Aixin Song; Junfeng Lu; Sujun Zheng; Zhongjie Hu; Lina Ma; Zhenhuan Cao; Hong Li; Yanhong Zheng; Shan Ren; Xinyue Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

Review 4.  Current hepatitis B treatment guidelines and future research directions.

Authors:  Jonathan Skupsky; Ke-Qin Hu
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

Review 5.  Functional cure for chronic hepatitis B: accessibility, durability, and prognosis.

Authors:  Aixin Song; Xiao Lin; Xinyue Chen
Journal:  Virol J       Date:  2021-06-03       Impact factor: 4.099

6.  Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).

Authors:  Jinlin Hou; Guiqiang Wang; Fusheng Wang; Jun Cheng; Hong Ren; Hui Zhuang; Jian Sun; Lanjuan Li; Jie Li; Qinghua Meng; Jingmin Zhao; Zhongping Duan; Jidong Jia; Hong Tang; Jifang Sheng; Jie Peng; Fengmin Lu; Qing Xie; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2017-11-12

7.  Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.

Authors:  Aixin Song; Xiaoxiao Wang; Junfeng Lu; Yi Jin; Lina Ma; Zhongjie Hu; Yanhong Zheng; Chengli Shen; Xinyue Chen
Journal:  J Viral Hepat       Date:  2021-02-08       Impact factor: 3.728

8.  Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.

Authors:  Minghui Li; Fangfang Sun; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Lu Zhang; Gang Wan; Wei Yi; Linqing Zhao; Yao Xie
Journal:  Virol Sin       Date:  2022-03-04       Impact factor: 6.947

9.  Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question.

Authors:  Trevor G Bell; Euphodia Makondo; Neil A Martinson; Anna Kramvis
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.